CLChase Doyne Latour

Chase Doyne Latour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chase Doyne Latour has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Jessie K. Edwards

    Department of Epidemiology, University of North Carolina at Chapel Hill

    3 shared publications
  • Jessie K. Edwards

    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA

    3 shared publications
  • Michele Jonsson Funk

    Department of Epidemiology, University of North Carolina at Chapel Hill

    3 shared publications
  • Michele Jonsson Funk

    Department of Epidemiology, Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    3 shared publications
  • Mollie E. Wood

    Department of Epidemiology, Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    3 shared publications
  • Charles Poole

    Department of Epidemiology, Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    2 shared publications

Latest Publications

  • Open Access

    Comparing causal estimands from sequential nested versus single point target trials: a simulation study

    by Catherine Wiener, Chase D Latour, Kathleen E Hurwitz, Xiaojuan Li, Catherine R Lesko, Alexander Breskin, M Alan Brookhart

    Sequential nested trial (SNT) emulation is a powerful approach for maximizing precision and avoiding time related biases. However, there exists little discussion about the implied causal estimands in comparison to a real-world single point trial. We used Monte Carlo simulation to compare treatment effect estimates from an SNT emulation that re-indexed patients annually and an SNT emulation with a treatment decision design to the estimates from a single point trial. We generated 5,000 cohorts of 5,000 people with 3 years of follow-up. For the single point trial, patients were randomized to initiate or not initiate treatment at Visit 1.For the SNT emulations, simulated patients could contribute up to two index dates. When disease severity did not modify the treatment effect, both SNT approaches returned treatment effect estimates identical to the single point trial. In the presence of treatment effect modification by disease severity, both SNT approaches returned treatment effect estimates that diverged from the single point trial even after confounding adjustment. These findings underscore the difficulties of interpreting causal estimands from an SNT emulation: the target population does not correspond to a single time point trial. Such implications are important for communicating study results for evidence-based decision-making.


  • Pregnancy identification method as a source of bias in studies of prenatal exposures using real-world data

    by Chase D Latour, Jessie K Edwards, Michele Jonsson Funk, Elizabeth A Suarez, Kim Boggess, Mollie E Wood

    Researchers typically identify pregnancies in healthcare data based on observed outcomes. This approach misses pregnancies that received prenatal care but whose outcomes were not recorded, potentially inducing selection bias in prenatal effect estimates. Alternatively, prenatal encounters can be used to identify pregnancies with unobserved outcomes, but this requires addressing loss to follow-up (LTFU). We simulated 10 000 000 pregnancies and estimated the total effect of treatment on preeclampsia. Across 36 scenarios, we varied the treatment effect on miscarriage and/or preeclampsia; percent LTFU (5% or 20%); and cause of LTFU: (1) measured covariates, (2) unobserved miscarriage, and (3) both. We created analytic samples to address LTFU—observed deliveries, observed deliveries and miscarriages, and all pregnancies—and estimated treatment effects using nonparametric direct standardization. Risk differences (RDs) and risk ratios (RRs) from the samples were similarly biased when LTFU was due to miscarriage (log-transformed RR bias: −0.12 to 0.33 among observed deliveries, −0.11 to 0.32 among observed deliveries and miscarriages, and −0.11 to 0.32 among all pregnancies). When predictors of LTFU were measured, only estimates among all pregnancies were unbiased (−0.27 to 0.33, −0.29 to 0.03, and −0.02 to 0.01, respectively). While including all pregnancies does not prevent bias, it quantifies the extent of selection, enabling direct assessment of its potential impact on findings.


  • Open Access

    Comparative effectiveness of initiating nifedipine versus labetalol in early gestation for chronic hypertension in pregnancy

    by Chase Doyne Latour, Madison Ponder, Kim A. Boggess, Jessie K. Edwards, Michele Jonsson Funk, Sharon Peacock Hinton, Mireille E Schnitzer, Elizabeth A Suarez, Mollie E Wood

    Background Limited data exist on the comparative effectiveness and safety of first-line medications to treat chronic hypertension in pregnancy. We compared nifedipine versus labetalol initiation before 23 weeks’ gestation for risk of pregnancy loss (miscarriage or stillbirth) and preterm birth (Methods We identified pregnancies in Merative’s MarketScan commercial claims data with estimated last menstrual periods between July 1, 2016 and February 1, 2022. We included those with a new nifedipine or labetalol fill before 23 weeks’ gestation. We estimated risks, risk differences (RDs) per 100 pregnancies, and risk ratios (RRs) among nifedipine versus labetalol initiators using a weighted Aalen-Johansen estimator to account for confounding and informative censoring. We also conducted a post hoc analysis to estimate the comparative effect of nifedipine versus labetalol on risk of preeclampsia. Results We identified 987 nifedipine and 4,570 labetalol initiators during the study period. The weighted risk of pregnancy loss was 7.0% among nifedipine and 6.0% among labetalol initiators (RD=1.1 [-0.7, 2.8]; RR=1.18 [0.87, 1.59]). Weighted risks of preterm birth were 29.4% versus 22.2%, respectively (RD=7.2 [3.9, 10.5], RR=1.32 [1.13, 1.55]). In post hoc analyses, the weighted risks of preeclampsia were 38.6% versus 33.9%, respectively (RD=4.7 [0.7, 8.7], RR=1.14 [1.01, 1.28]). Findings were consistent across various sensitivity analyses. Conclusions Compared to labetalol initiators, nifedipine initiators experienced an increased risk of preterm birth but not pregnancy loss. The elevated risk of preterm birth may be explained by an increased risk of preeclampsia among nifedipine initiators, resulting in medically indicated preterm birth. What is new? Initiating nifedipine, compared to labetalol, before 23 weeks’ gestation as a first-line antihypertensive was associated with a 7.2 percentage point increased risk of preterm live birth (95% CI: 3.9, 10.5) and 4.7 percentage point increased risk of preeclampsia (95% CI: 0.7, 8.7). Nifedipine and labetalol were associated with a similar risk of pregnancy loss (risk difference: 1.1 per 100 pregnancies [95% CI: -0.7, 2.8]). These findings were robust across multiple sensitivity analyses. What are the clinical implications? Initiating labetalol, compared to nifedipine, prior to 23 weeks’ gestation for treatment of chronic hypertension in pregnancy may lead to lower risk of preeclampsia and preterm live birth in real-world settings. While high-quality data from clinical trials clearly support antihypertensive therapy for chronic hypertension in pregnancy, our findings illustrate that the first-line medications may have different comparative safety and effectiveness profiles. These data are important for informing shared decision-making between providers and patients managing chronic hypertension in pregnancy.


  • Healthy Live Births as Censoring Versus Competing Events in Studies of Prenatal Medication Use

    by Chase D. Latour, Mark Klose, Jessie K. Edwards, Zoey Song, Michele Jonsson Funk, Mollie E. Wood

    Background: Pregnancy loss is recognised as a competing event in studies of prenatal medication use. A healthy live birth also precludes subsequent pregnancy outcomes, yet is often censored in time‐to‐event analyses. Objectives: Using a Monte Carlo simulation, we examined bias resulting from censoring versus accounting for healthy live birth as a competing event in estimates of the total effect of prenatal medication use on pregnancy outcomes. Methods: We simulated 2000 cohorts of 7500 conceptions with chronic hypertension under 12 treatment profiles. Ongoing pregnancies were indexed into the trial and randomly assigned to initiate or not initiate antihypertensives. Using time‐to‐event methods, we estimated absolute risks, risk differences (RD) per 100 pregnancies, and risk ratios (RR) for two outcomes, mirroring a prior trial: (i) composite fetal death or severe prenatal preeclampsia and (ii) small for gestational age (SGA) live birth. For the composite outcome, we conducted analyses where non‐preeclamptic live birth was: (1) a censoring event and (2) a competing event. For SGA live birth, we conducted analyses where fetal death and non‐SGA live birth were: (1) censoring events; (2) a competing event and censoring event, respectively; and (3) competing events. Results: For the composite outcome, censoring non‐preeclamptic live births overestimated the absolute risk by 42.3 to 49.1 percentage points; RD and RR estimates were biased (e.g., RD bias range −6.18 to 0.46). For SGA live birth, analyses censoring non‐SGA live births (with or without fetal death as a competing event) overestimated absolute risk by 30.0 to 37.7 and 40.9 to 52.4 percentage points on average; RD and RR estimates were biased (e.g., RD bias range −7.45 to 0.79 and −9.62 to 1.81, respectively). Analyses in which healthy live births were modelled as competing events produced unbiased risks, RDs and RRs. Conclusions: Censoring healthy live births resulted in overestimated risks as well as biased and imprecise total treatment effect estimates. Such inaccuracies about risks undermine informed patient–provider decision‐making.


  • Open Access

    Healthy Live Births Should be Considered as Competing Events when Estimating the Total Effect of Prenatal Medication Use on Pregnancy Outcomes

    by Chase D. Latour, Mark Klose, Jessie K. Edwards, Zoey Song, Michele Jonsson Funk, Mollie E. Wood

    Pregnancy loss is recognized as an important competing event in studies of prenatal medication use. However, a healthy live birth also precludes subsequent adverse pregnancy outcomes, yet these events are often censored. Using Monte Carlo simulation, we examine bias that results from failure to account for healthy live birth as a competing event in estimates of the total effect of prenatal medication use on pregnancy outcomes. We simulated data for 12 trials estimating the effect of antihypertensive initiation versus non-initiation on two outcomes: (1) composite fetal death or severe prenatal preeclampsia and (2) small-for-gestational-age (SGA) live birth. We used time-to-event methods to estimate absolute risks, risk differences and risk ratios. For the composite outcome, we conducted two analyses where non-preeclamptic live birth was (1) a censoring event and (2) a competing event. For SGA live birth, we conducted three analyses where fetal death and non-SGA live birth were (1) censoring events, (2) a competing event and censoring event, respectively; and (3) competing events. In all analyses, censoring healthy live births led to inflated absolute risk estimates as well as bias and imprecise treatment effect estimates. Studies of prenatal exposures on pregnancy outcomes should analyze healthy live births as competing risks to estimate unbiased total treatment effects.

  • Hazard Ratios and Alternative Effect Measures: An Applied Illustration

    by Chase D. Latour, I‐Hsuan Su, Megan Delgado, Virginia Pate, Charles Poole, Jessie K. Edwards, Til Stürmer, Jennifer L. Lund, Michele Jonsson Funk

    Purpose: Although the limitations of hazard ratios (HRs) for quantifying treatment effects in right‐censored data have been widely discussed, HRs are still preferentially reported over other, more interpretable effect measures. This may stem from the fact that there are few applied examples that directly contrast the HR and its interpretation with alternative effect measures.Methods: We analyzed data from two randomized clinical trials comparing panitumumab plus standard‐of‐care chemotherapy (SOCC) with SOCC alone as first‐ and second‐line treatment for metastatic colorectal cancer. We report the effect of treatment with panitumumab on progression‐free survival (PFS) using a Cox proportional hazards model to estimate the HR and the Kaplan‐Meier estimator of cumulative incidence (risk). Further analyses included examining the cumulative incidence curves; kernel‐smoothed, non‐parametric hazards curves; fitting the Cox model with a continuous time variable; and estimating restricted mean survival as well as median survival.Results: The HR was 0.82 (95% confidence interval [CI]: 0.71, 0.93), while the risk ratio (or relative risk [i.e., ratio of the cumulative incidence among the treated versus comparator]) was 0.99 (95% CI: 0.96, 1.02). These two measures suggest apparently different conclusions: either a treatment benefit or no effect. Through subsequent analyses, we demonstrated that, while the cumulative incidence of the outcome was similar by the end of follow‐up regardless of treatment, the panitumumab treated group experienced longer PFS than those randomized to SOCC. Substantial nonproportional hazards were evident with panitumumab treatment reducing the hazard of progression/mortality during the first ~1.75 years but associated with an increased hazard of progress/mortality thereafter.Discussion: This example underscores the difficulties in interpreting HRs, particularly in the setting of qualitative violations of proportional hazards, and the value of quantifying treatment effects via multiple effect measures.


  • Use of sensitivity analyses to assess uncontrolled confounding from unmeasured variables in observational, active comparator pharmacoepidemiologic studies: a systematic review

    by Chase D Latour, Megan Delgado, I-Hsuan Su, Catherine Wiener, Clement O Acheampong, Charles Poole, Jessie K Edwards, Kenneth Quinto, Til Stürmer, Jennifer L Lund, et al.

    Understanding the potential for, and direction and magnitude of uncontrolled confounding is critical for generating informative real-world evidence. Many sensitivity analyses are available to assess robustness of study results to residual confounding, but it is unclear how researchers are using these methods. We conducted a systematic review of published active-comparator cohort studies of drugs or biologics to summarize use of sensitivity analyses aimed at assessing uncontrolled confounding from an unmeasured variable. We reviewed articles in 5 medical and 7 epidemiologic journals published between January 1, 2017, and June 30, 2022. We identified 158 active-comparator cohort studies: 76 from medical and 82 from epidemiologic journals. Residual, unmeasured, or uncontrolled confounding was noted as a potential concern in 93% of studies, but only 84 (53%) implemented at least 1 sensitivity analysis to assess uncontrolled confounding from an unmeasured variable. The most common analyses were E-values among medical journal articles (21%) and restriction on measured variables among epidemiologic journal articles (22%). Researchers must rigorously consider the role of residual confounding in their analyses and the best sensitivity analyses for assessing this potential bias. This article is part of a Special Collection on Pharmacoepidemiology.


  • Defining, Measuring, and Evaluating Prenatal Care in Insurance Claims Data

    by Elizabeth Simmons, Mekhala V. Dissanayake, Jacob C. Kahrs, Chase D. Latour, Oluwasolape Olawore, Lauren M. Kucirka, Mollie E. Wood

    Purpose of Review The objective of this paper is to discuss the complexities of identifying prenatal care visits in insurance claims databases, review existing methods to identify prenatal care encounters, and explore how different study goals should inform the definition of prenatal care employed by investigators. Recent Findings Insurance claims data are routinely used to conduct perinatal epidemiology studies focused on the effects of medical interventions. Prenatal care, an important medical intervention and an indicator of ongoing pregnancy, lacks a consistent definition among clinical and research-based sources. Summary We have categorized definitions of prenatal care in three groups: all healthcare received while pregnant, pregnancy-specific healthcare, and guideline-concordant healthcare. In studies using insurance claims data, we found five common methods to identify prenatal care encounters. Using example study goals, we outline important considerations investigators must make when applying different methods to identify prenatal care visits in studies using insurance claims data.


  • Open Access

    Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study

    by Chase D Latour, Leah J McGrath, Mary Clouser, Carrie Nielson, Ying Yu, Akhila Balasubramanian, Alexander Breskin, M Alan Brookhart

    Purpose: Regression-to-the-mean (RTM) is a statistical phenomenon that may occur in epidemiologic studies where inclusion in the study cohort is contingent upon experiencing a laboratory/clinical measurement beyond a defined threshold. When differential across treatment groups, RTM could bias the final study estimate. This poses substantial challenges in observational studies that index patients upon experiencing extreme laboratory or clinical values. Our objective was to investigate propensity score-based methods as a tool for mitigating this source of bias via simulation. Methods: We simulated a noninterventional comparative effectiveness study, comparing treatment with romiplostim to standard-of-care therapies for immune thrombocytopenia (ITP), a disease characterized by low platelet counts. Platelet counts were generated from normal distributions according to the underlying ITP severity, a strong confounder of treatment and outcome. Patients were assigned treatment probabilities based upon ITP severity, which created varied levels of differential and non-differential RTM. Treatments were compared via the difference in median platelet counts during 23 weeks of follow-up. We calculated four summary metrics of the platelet counts measured prior to cohort entry and built six propensity score models to adjust for those variables. We adjusted for these summary metrics using inverse probability of treatment weights. Results: Across all simulated scenarios, propensity score adjustment reduced bias and increased precision of the treatment effect estimator. Adjusting for combinations of the summary metrics was most effective at reducing bias. Adjusting for the mean of prior platelet counts or the difference between the cohort-qualifying platelet count and the largest prior count eliminated the most bias when assessed individually. Conclusion: These results suggest that differential RTM could be reasonably addressed by propensity score models with summaries of historical laboratory values. This approach can be easily applied to any comparative effectiveness or safety study, though investigators should carefully consider the best summary metric for their data.